^
    1m
    Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells (clinicaltrials.gov)
    P1, N=27, Not yet recruiting, UNC Lineberger Comprehensive Cancer Center | Initiation date: Mar 2024 --> Jul 2024
    Trial initiation date • CAR T-Cell Therapy
    |
    cyclophosphamide • fludarabine IV • CAR.B7-H3 T
    2ms
    Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells (clinicaltrials.gov)
    P1, N=42, Not yet recruiting, UNC Lineberger Comprehensive Cancer Center
    New P1 trial
    |
    cyclophosphamide • fludarabine IV • CAR.B7-H3 T
    2ms
    Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells (clinicaltrials.gov)
    P1, N=27, Not yet recruiting, UNC Lineberger Comprehensive Cancer Center
    New P1 trial • CAR T-Cell Therapy
    |
    cyclophosphamide • fludarabine IV • CAR.B7-H3 T
    6ms
    Autologous CAR-T Cells Targeting B7-H3 in PDAC (clinicaltrials.gov)
    P1, N=27, Not yet recruiting, UNC Lineberger Comprehensive Cancer Center
    New P1 trial • CAR T-Cell Therapy
    |
    CD276 (CD276 Molecule)
    |
    CAR.B7-H3 T
    over1year
    Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc (clinicaltrials.gov)
    P1, N=36, Recruiting, UNC Lineberger Comprehensive Cancer Center | Not yet recruiting --> Recruiting | Trial primary completion date: May 2030 --> Oct 2024
    Enrollment open • Trial primary completion date • CAR T-Cell Therapy
    |
    CD276 (CD276 Molecule)
    |
    CAR.B7-H3 T
    2years
    Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc (clinicaltrials.gov)
    P1, N=36, Not yet recruiting, UNC Lineberger Comprehensive Cancer Center
    New P1 trial • CAR T-Cell Therapy
    |
    CD276 (CD276 Molecule)
    |
    CAR.B7-H3 T